Mucoadhesive drug delivery systems (MDDS) are designed to enhance the residence time of a drug at a specific site in the body, primarily on mucosal surfaces.
Suzhou Ribo Life Science recently inked a deal with Qilu Pharmaceutical, granting them rights to develop, produce, and market PCSK9 inhibitor drug RBD7022 (SR043) in Greater China.
On 3 Dec 2023, the latest clinical result of MCLA-129, an anti-EGFR/c-MET bispecific antibody, for the treatment of head and neck squamous cell cancer (HNSCC) was reported in 2023 ESMO_ASIA.
On 2 Dec 2023, the latest clinical trial about Sintilimab in combination with anlotinib in 2023 ESMO_ASIA further demonstrated the therapeutic benefits.
Selecting TYK2 inhibitors can reduce the inhibition of other immune-related pathways in the body, reduce the risk of infection, and be safer in clinical practice.